Ivabradin Medical Valley

Ivabradine, the active ingredient in Ivabradin Medical Valley, is a If channel inhibitor presented as an oral formulation for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradin Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate in several cardiovascular conditions.

Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers heart rate, improves symptoms and may reduce hospitalisations.

Ivabradine may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Visual disturbances (phosphenes or luminous phenomena) - Bradycardia (slow heart rate) - Headache - Dizziness - Fatigue - Nausea

Serious or Rare Side Effects: - Severe bradycardia requiring medical attention - Atrial fibrillation or other arrhythmias - Symptomatic hypotension - Persistent visual impairment - Severe allergic reactions (rash, angioedema)

Before initiating ivabradine, clinicians should consider several safety factors.

Cardiac monitoring: assess baseline heart rate and rhythm. Concomitant beta‑blockers: avoid excessive bradycardia by adjusting doses. CYP3A4 inhibitors: dose may need reduction when strong inhibitors are used. Renal or hepatic impairment: use with caution and monitor response. Pregnancy and lactation: safety not established; avoid unless clearly needed. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Ivabradine interacts with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure. - Concomitant bradycardic agents (beta‑blockers, digoxin): risk of severe bradycardia. - Other If channel inhibitors (e.g., ranolazine): additive heart‑rate lowering.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may raise plasma levels. - QT‑prolonging drugs: monitor ECG for arrhythmia risk. - Excess alcohol: can enhance bradycardic effect.